In one paragraphArticle in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Daniel FlenderCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.
Dana LiuCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0002-4497-1701 Jenny Hong HoangLife Science Services, Merck Life Science KGaA, 64293 Darmstadt, Germany.
Max HesseGlobal Drug Product Development, Merck Healthcare KGaA, 64293 Darmstadt, Germany.
Diana Campillo-DavoLaboratory of Experimental Hematology (LEH), Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0002-6080-3935 Eva LionLaboratory of Experimental Hematology (LEH), Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0002-2420-0301 Jonas Van AudenaerdeCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0002-5619-1913 Stefan SchillerGlobal Drug Product Development, Merck Healthcare KGaA, 64293 Darmstadt, Germany.
Johanna SimonLife Science Services, Merck Life Science KGaA, 64293 Darmstadt, Germany.
Simon GeisslerGlobal Drug Product Development, Merck Healthcare KGaA, 64293 Darmstadt, Germany.
Evelien SmitsCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0001-9255-3435 Karsten MäderFaculty I of Natural Sciences, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, 06108 Halle (Saale), Germany.ORCID 0000-0003-1613-6976 Hannah ZaryouhCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0002-4567-1399 Funding
Horizon Europe Framework Programme (HORIZON) ID 101057250
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
eGFP mRNAelectroporationhuman dendritic cellionizable lipidlipid nanoparticlestransfection efficiencyuridine modification
Identifiers
PMID42076056
PMCPMC13119134
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390